MMP2 and glioma: Ongoing clinical trial activities of CAR T cells in glioma include different CAR-T targets like B7-H3 (NCT04077866; NCT05241392; NCT04385173), matrix metallopeptidase 2 (MMP2; NCT05627323; NCT04214392), CD70 (NCT05353530), as well as EGFRvIII (NCT06186401).15 Additionally, there is a study combining IL-13Rα2-targeted CAR-T cells with checkpoint inhibitors (NCT04003649).